Study on the impact of the specialized centralized procurement for insulin on the daily cost and affordability of insulin in China

LEI Fengping; ZHANG Jieqiong; LIU Xingchen; WEI Haoqi; LIU Xingyu; YANG Caijun

doi:10.6039/j.issn.1001-0408.2025.12.11

您当前的位置：

首页 >

文章列表页 >

Study on the impact of the specialized centralized procurement for insulin on the daily cost and affordability of insulin in China

更新时间：2025-09-23

- Study on the impact of the specialized centralized procurement for insulin on the daily cost and affordability of insulin in China
- ZHONGGUO YAOFANG Vol. 36, Issue 12, Pages: 1483-1487(2025)
- 作者机构：
  
  1.西安交通大学药学院，西安　710061
  2.西安航天医院药剂科，西安　710100
  3.宜兴市生命健康产业创新服务中心，江苏无锡　214000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.12.11
  CLC： R977.1+5;R956
- Received：15 October 2024，
  
  Revised：2025-05-23，
  
  Accepted：26 May 2025，
  
  Published：30 June 2025
- 稿件说明：
移动端阅览
雷凤萍,章洁琼,刘星宸,等.胰岛素专项集采对我国胰岛素日费用和可负担性的影响研究 [J].中国药房,2025,36(12):1483-1487.

LEI Fengping,ZHANG Jieqiong,LIU Xingchen,et al.Study on the impact of the specialized centralized procurement for insulin on the daily cost and affordability of insulin in China[J].ZHONGGUO YAOFANG,2025,36(12):1483-1487.
雷凤萍,章洁琼,刘星宸,等.胰岛素专项集采对我国胰岛素日费用和可负担性的影响研究 [J].中国药房,2025,36(12):1483-1487. DOI： 10.6039/j.issn.1001-0408.2025.12.11.

LEI Fengping,ZHANG Jieqiong,LIU Xingchen,et al.Study on the impact of the specialized centralized procurement for insulin on the daily cost and affordability of insulin in China[J].ZHONGGUO YAOFANG,2025,36(12):1483-1487. DOI： 10.6039/j.issn.1001-0408.2025.12.11.

摘要

目的

评估胰岛素专项集采政策对我国胰岛素日费用和可负担性的影响，为相关政策的完善提供数据支撑。

方法

通过各省份独立的药品集中采购平台收集胰岛素专项集采前后（2021年10－12月、2022年10－12月）的胰岛素采购数据，以各类胰岛素的限定日费用（DDDc）为指标，分析专项集采前后的日费用变化；以各类胰岛素年支出占年人均可支配收入的百分比（即年支出占比）为指标，评估专项集采前后各类胰岛素的可负担性变化。

结果

专项集采后，各类胰岛素DDDc的降幅为20.7%～71.8%，平均降幅为45.7%，且三代胰岛素的降幅超过二代胰岛素；胰岛素年支出占比的降幅为24.3%～73.4%，平均降幅为48.5%，预混胰岛素类似物的降幅最大（73.4%）。专项集采后，所有纳入省份的胰岛素DDDc均有所下降；除广西（10.2%）外，其余各省份胰岛素的平均年支出占比均降至10%以内。

结论

胰岛素专项集采政策显著降低了胰岛素费用、提高了可负担性、降低了糖尿病患者的经济负担，但省际及胰岛素类型间的日费用和可负担性差异明显，需重点关注。

Abstract

OBJECTIVE

To evaluate the impact of the specialized centralized procurement policy for insulin on daily cost and affordability of insulin， and provide data support for the enhancement of relevant policies.

METHODS

In this research， the insulin purchasing data were obtained from provincial centralized procurement platforms in provinces before and after the specialized centralized procurement of insulin （October-December 2021 and October-December 2022）， and the cost variations of insulin before and after the centralized procurement were analyzed by the defined daily dose cost （DDDc） of various types of insulins. The changes in the affordability of various types of insulins before and after the specialized centralized procurement were evaluated， using the percentage of annual expenditure on various types of insulins relative to annual per capita disposable income （i.e. the proportion of annual expenditure） as an indicator.

RESULTS

After the specialized centralized procurement， DDDc of various types of insulins decreased by 20.7%-71.8%， with an average reduction of 45.7%. Moreover， the reduction in DDDc for third-generation insulin exceeded that for second-generation insulin. The reduction in the proportion of annual expenditure on insulin ranged from 24.3% to 73.4%， with an average decrease of 48.5%. Premixed insulin analogs experienced the greatest reduction （73.4%）. Following the specialized centralized procurement， DDDc of insulin decreased in all provinces. Except for Guangxi （10.2%）， the average proportion of annual expenditure on insulin in the remaining provinces dropped to below 10%.

CONCLUSIONS

The specialized centralized procurement policy for insulin has significantly reduced insulin costs and improved affordability， thereby alleviating the economic pressure on patients with diabetes. There are notable cost disparities among provinces and among insulin categories， which require attention.

关键词

Keywords

references

Internal Diabetes Federation . Diabetes global report 2000 - 2050 [EB/OL ] . [ 2024-09-15 ] . https：//diabetesatlas.org/data/ https://diabetesatlas.org/data/ .

章玲，王雅男，朱佳文，等 . 胰岛素集采背景下中选生产企业扩产路径研究 [J ] . 中国医药工业杂志， 2022 ， 53 （ 5 ）： 740 - 746 .

《落实国家组织胰岛素专项集中带量采购政策专家共识》专家组 . 落实国家组织胰岛素专项集中带量采购政策专家共识 [J ] . 中国药业， 2022 ， 31 （ 19 ）： 1 - 7 .

李淑娟，胡剑，李育 . 基于价格指数的安徽省药品集采政策实施效果比较研究 [J ] . 中国卫生经济， 2023 ， 42 （ 6 ）： 13 - 16 .

中华医学会糖尿病学分会 . 中国2型糖尿病防治指南：2020年版 [J ] . 国际内分泌代谢杂志， 2021 ， 41 （ 5 ）： 482 - 548 .

WHO Collaborating Centre for Drug Statistics Methodo-logy . ATC/DDD index [EB/OL ] . [ 2024-09-15 ] . https：//www.whocc.no/atc_ddd_index/ https://www.whocc.no/atc_ddd_index/ .

冉兴无，母义明，朱大龙，等 . 成人2型糖尿病基础胰岛素临床应用中国专家指导建议： 2020版 [J ] . 中国糖尿病杂志， 2020 ， 28 （ 10 ）： 721 - 728 .

CHEN C ， LIU X Y ， ZHANG J Q ， et al . Changes in insulin utilization in China from 2020 to 2022 [J ] . Diabetes Obes Metab ， 2024 ， 26 （ 12 ）： 5681 - 5689 .

上海阳光医药采购网 . 关于公布全国药品集中采购（胰岛素专项）中选结果的通知 [EB/OL ] . （ 2021-11-30 ）[ 2024-04-20 ] . https：//www.smpaa.cn/gjsdcg/2021/11/30/10435.shtml https://www.smpaa.cn/gjsdcg/2021/11/30/10435.shtml .

上海阳光医药采购网 . 全国药品集中采购（胰岛素专项）拟中选结果公示 [EB/OL ] .（ 2021-11-26 ）[ 2024-04-20 ] . https：//www.smpaa.cn/gjsdcg/2021/11/26/10428.shtml https://www.smpaa.cn/gjsdcg/2021/11/26/10428.shtml .

黄理，周颖玉，王冉，等 . 2013－2018年药品费用及价格变化情况研究：以糖尿病用药为例 [J ] . 中国卫生经济， 2020 ， 39 （ 8 ）： 18 - 22 .

林丽敏，彭晓青，唐榕，等 . 国家药品集中采购政策对药品经济可及与医院用药结构的影响 [J ] . 中国药房， 2023 ， 34 （ 24 ）： 2968 - 2974 .

BANG C ， MORTENSEN M B ， LAURIDSEN K G ， et al . Trends in antidiabetic drug utilization and expenditure in Denmark：a 22-year nationwide study [J ] . Diabetes Obes Metab ， 2020 ， 22 （ 2 ）： 167 - 172 .

管晓东，林其敏，信枭雄，等 . 药品可负担性评价方法研究 [J ] . 中国药房， 2015 ， 26 （ 28 ）： 3892 - 3895 .

周盛明，李嘉瑶，周静，等 . 中国罕见病用药可负担性评价 [J ] . 中国药业， 2021 ， 30 （ 1 ）： 9 - 15 .

宁艳阳 . 胰岛素专项集采有哪些关键点 [J ] . 中国卫生， 2022 （ 3 ）： 31 - 34 .

薛天祺，葛靖，路云，等 . 全国胰岛素专项集中带量采购规则和中选成效分析 [J ] . 中国卫生资源， 2022 ， 25 （ 1 ）： 44 - 48 .

代雪飞 . 胰岛素专项集采政策落地对我院降糖药物应用联动影响分析 [J ] . 实用药物与临床， 2023 ， 26 （ 2 ）： 185 - 192 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Price and affordability analysis of non-free anti-HIV drugs and therapeutic regimen in China

西北某县级公立医院药品使用情况、价格水平及可负担性分析

基于WHO/HAI标准化调查法对陕西省慢性病用药价格与供应情况的调查分析

我国基本药物可负担性评价实证研究

基于WHO/HAI标准化法的陕西省零售药店儿童基本药物可获得性及价格研究Δ

Related Author

WANG Xuanhui

GONG Chunbo

殷实卞鹰

姜明欢王　乐王文娟王　潇方　宇杨世民

管晓东信枭雄刘洋史录文

王　潇杨世民方　宇姜明欢武丽娜

张筱林?邵青?

董玉珍?王辉?勾旭?方世平?

Related Institution

School of Pharmacy， Shandong University of Traditional Chinese Medicine

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰